http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 박교준 (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
정부의 '약가제도 개편 및 혁신형 제약기업 지원' 정책의 효과성 연구
신광수,박교준,박하영 한국보건경제정책학회 2020 보건경제와 정책연구 Vol.26 No.1
The Korean government implemented a policy in 2012 to bring structural changes to the pharmaceutical industry whose dependence on generic drugs was high and innovation capacity to develop new drugs was low. The policy was comprised of two parts, price reduction of generic drugs and supports of selected innovative pharmaceutical firms with tax credits, higher drug prices, and various managerial benefits. The objective of this study was to assess the impacts of the policy by examining firm level responses in internal research and development (R&D) investment and effort to acquire external R&D resources through strategic alliances and merger and acquisitions (M&As). The study also examined innovation outputs (numbers of patent registration and clinical trials) which are results of R&D inputs and the final financial outcome (revenue). The study collected data for 46 publicly listed firms on the KOSPI and KOSDAQ markets during 2009-2016, 20 selected innovative firms and 26 non-selection firms, and compared the study variables of the two groups to estimate the impacts with differences-in-differences (DD) and panel regression DD with control variables. Results indicated that selected innovative firms were superior to their couterpart firms in R&D inputs, innovation outputs, and financial outcome in the first place, and the government supports strengthened their superiority in internal R&D investments, alliances and M&As, and patent registration. However, the policy did not have any influence on the number of clinical trials and revenue, and the reduction of drug prices did not have statistically significant impacts on the study variables either. The study contributed in providing policy makers and firm managers with directions for the advancement of the Korean pharmaceutical industry despite the limitation of short data period and the generalizability problem.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
